Last reviewed · How we verify

NCT05761626

Mechanical Power Normalized to Compliance in ARDS

Completed Last updated 30 April 2025
What this trial tests

trial testing MP/Crs assessment < = 0.48 J/min/ml/cmH2O in Acute Respiratory Distress Syndrome in 39 participants. Completed in 10 February 2023.

Timeline
1 March 2016
Primary endpoint
10 February 2023
10 February 2023

Quick facts

Lead sponsorRamos Mejía Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment39
Start date1 March 2016
Primary completion10 February 2023
Estimated completion10 February 2023
Sites1 location across Argentina

Drugs / interventions tested

Conditions studied

Sponsor

Ramos Mejía Hospital

Who can join

15 and older, any sex, with Acute Respiratory Distress Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Mechanical power (MP) is a summary variable, which includes static and dynamic respiratory parameters, is associated with ventilator-induced lung injury. MP is transferred primarily to smaller functional lung size, often referred to as "baby lung" (BL). Functional lung size (BL) is associated with respiratory system compliance (Crs). For this reason, MP normalized to Crs (MP/Crs) could be an important parameter to evaluate. The objectives of this study were to compare variables according to the MP/Crs cut-off point and to identify the MP components associated with MP/Crs.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Respiratory Distress Syndrome

Currently open trials in the same condition.

Other Ramos Mejía Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05761626.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing